更年期市场规模、份额、趋势分析报告：按治疗方法、地区、细分市场预测，2024-2030

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (North America, Europe, Latin America), And Segment Forecasts, 2024 - 2030

出版日期: 2023年11月24日 | 出版商:

Grand View Research | 英文 200 Pages | 商品交期: 2-10个工作天内

价格

简介目录图表

更年期市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球更年期市场规模将达244亿美元，2024年至2030年复合年增长率为5.37%。

停经后症候群盛行率上升、人们对更年期相关健康问题的认识不断提高以及女性健康应用程式的高采用率等因素预计将推动市场成长。

越来越多的研究支持营养补充食品荷尔蒙替代疗法的益处，预计该市场将受到推动。市面上食品许多营养补充含有黑升麻、红三叶草、大豆异黄酮和琥珀烯等成分。製造商也在努力开发新产品来解决更年期症状。例如，Morphus 在 2023 年推出了多种补充品产品，以解决更年期和更年期的一些最紧迫的症状。推出的第一个产品是 FiberUs，这是一种由瓜尔胶纤维製成的无味水溶性益生元纤维。

由于营养补充预约延迟、荷尔蒙替代治疗重新推迟以及零售药局和线上管道容易获得成药，疫情后对膳食补充剂和成药的需求增加。然而，由于监管的放鬆和更年期意识的增强，市场目前正在稳定。

FDA核准用于治疗潮热和盗汗的药物的快速增加也是推动市场成长的主要因素。 2023 年 5 月，FDA核准了一种新的非荷尔蒙药物，用于解决更年期经常出现的盗汗和潮热问题。这种处方药称为 fesolinetant，专为无法接受荷尔蒙治疗并患有血管舒缩症状的人（例如乳癌倖存者）而设计。该药物以 Veozah 品牌出售。

更年期市场报告亮点

根据治疗方法，营养补充食品领域预计将在 2023 年主导市场，并在预测期内实现最快的成长。该行业的成长可归因于多种因素，包括老年人口的增加和创新产品的推出。例如，2021年4月，韩国营养补充食品Pulmuone推出了一款含有大豆和啤酒花萃取物的产品，用于治疗与更年期相关的症状。
成药治疗领域分为非荷尔蒙产品和荷尔蒙产品。已到更年期的女性越来越多地使用非处方 (OTC) 荷尔蒙产品。此细分市场的主要产品包括局部黄体酮、Ibuprofen、磊晶(DHEA) 和褪黑激素。
2023年，北美地区占销售份额最大。老年妇女的用餐意识不断增强，对特定营养需求的需求也增加。
2022 年1 月，Amyris, Inc. 宣布已签订独家协议，收购MenoLabs, LLC. 的资产，MenoLabs, LLC. 是一家由女性创办的公司，专注于更年期治疗、女性健康研究和提高公众对更年期的了解。
2023年1月，女性健康品牌O Positive推出首款更年期维生素软糖，为更年期女性提供一种方便又美味的方式来管理她们的症状。

市场区隔和范围
市场体系展望
- 母市场展望
- 相关/附随市场展望
市场趋势及展望
市场动态
- 更多女性进入闭经
- 提高对更年期及其治疗的认识
- 扩大更年期照护的机会和创新
- 越来越多的研究支持营养补充食品的益处
市场抑制因素分析
- 与更年期和产品副作用相关的社会耻辱
- 缺乏明确规定
营商环境分析
- PESTLE分析
- 波特五力分析
COVID-19感染疾病的影响分析

第四章治疗业务分析

更年期市场：治疗变异分析
营养补充食品
成药
- 荷尔蒙产品
- 非荷尔蒙产品

第五章区域业务分析

2023 年和 2030 年按地区分類的闭经市场占有率
北美洲
- 美国
- 加拿大
欧洲
- 英国
- 德国
- 法国
- 义大利
- 西班牙
- 瑞典
- 挪威
- 丹麦
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 泰国
- 韩国
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东/非洲
- 南非
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
- 科威特

第六章竞争形势

公司分类
策略规划
- 併购
- 合作
- 新产品发布
参与企业概况
- Bayer AG
- Theramex
- Abbvie Inc.
- Abbott
- Pure Encapsulations, LLC
- Dr. Reddy's Laboratories Ltd.
- Rainbow Light
- PADAGIS LLC

简介目录图表

Product Code: GVR-4-68039-434-2

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

Based on treatment, the dietary supplements treatment segment dominated the market in 2023 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
North America held the largest revenue share in 2023. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Treatment Segment
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. Gvr's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
- 3.4.1. Growing number of women undergoing menopause
- 3.4.2. Increasing awareness about menopause and its treatment
- 3.4.3. Growing opportunities and innovations in menopause treatment
- 3.4.4. Increasing research supporting advantages of dietary supplements
3.5. Market Restraint Analysis
- 3.5.1. Social stigma associated with menopause and adverse effects of products
- 3.5.2. Lack of well-defined regulations
3.6. Business Environment Analysis
- 3.6.1. PESTLE Analysis
- 3.6.2. Porter's Five Forces Analysis
3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis

4.1. Menopause Market: Treatment Movement Analysis
4.2. Dietary Supplements
- 4.2.1. Dietary Supplements Market, 2018 - 2030 (USD Million)
4.3. OTC Pharma Products
- 4.3.1. OTC Pharma Products Market, 2018 - 2030 (USD Million)
- 4.3.2. Hormonal Products
  - 4.3.2.1.1. Hormonal Products Market, 2018 - 2030 (USD Million)
- 4.3.3. Non-hormonal Products
  - 4.3.3.1.1. Non-hormonal Products Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

5.1. Menopause Market Share By Region, 2023 & 2030
5.2. North America
- 5.2.1. North America Menopause Market, 2018 - 2030 (USD Million)
- 5.2.2. U.S.
  - 5.2.2.1. Key Country Dynamics
  - 5.2.2.2. Regulatory Framework/Scenario
  - 5.2.2.3. Competitive Scenario
  - 5.2.2.4. U.S. Menopause Market, 2018 - 2030 (USD Million)
- 5.2.3. Canada
  - 5.2.3.1. Key Country Dynamics
  - 5.2.3.2. Regulatory Framework/Scenario
  - 5.2.3.3. Competitive Scenario
  - 5.2.3.4. Canada Menopause Market, 2018 - 2030 (USD Million)
5.3. Europe
- 5.3.1. Europe Menopause Market, 2018 - 2030 (USD Million)
- 5.3.2. UK
  - 5.3.2.1. Key Country Dynamics
  - 5.3.2.2. Regulatory Framework/Scenario
  - 5.3.2.3. Competitive Scenario
  - 5.3.2.4. Germany Menopause Market, 2018 - 2030 (USD Million)
- 5.3.3. Germany
  - 5.3.3.1. Key Country Dynamics
  - 5.3.3.2. Regulatory Framework/Scenario
  - 5.3.3.3. Competitive Scenario
  - 5.3.3.4. UK Menopause Market, 2018 - 2030 (USD Million)
- 5.3.4. France
  - 5.3.4.1. Key Country Dynamics
  - 5.3.4.2. Regulatory Framework/Scenario
  - 5.3.4.3. Competitive Scenario
  - 5.3.4.4. France Menopause Market, 2018 - 2030 (USD Million)
- 5.3.5. Italy
  - 5.3.5.1. Key Country Dynamics
  - 5.3.5.2. Regulatory Framework/Scenario
  - 5.3.5.3. Competitive Scenario
  - 5.3.5.4. Italy Menopause Market, 2018 - 2030 (USD Million)
- 5.3.6. Spain
  - 5.3.6.1. Key Country Dynamics
  - 5.3.6.2. Regulatory Framework/Scenario
  - 5.3.6.3. Competitive Scenario
  - 5.3.6.4. Spain Menopause Market, 2018 - 2030 (USD Million)
- 5.3.7. Sweden
  - 5.3.7.1. Key Country Dynamics
  - 5.3.7.2. Regulatory Framework/Scenario
  - 5.3.7.3. Competitive Scenario
  - 5.3.7.4. Sweden Menopause Market, 2018 - 2030 (USD Million)
- 5.3.8. Norway
  - 5.3.8.1. Key Country Dynamics
  - 5.3.8.2. Regulatory Framework/Scenario
  - 5.3.8.3. Competitive Scenario
  - 5.3.8.4. Norway Menopause Market, 2018 - 2030 (USD Million)
- 5.3.9. Denmark
  - 5.3.9.1. Key Country Dynamics
  - 5.3.9.2. Regulatory Framework/Scenario
  - 5.3.9.3. Competitive Scenario
  - 5.3.9.4. Denmark Menopause Market, 2018 - 2030 (USD Million)
5.4. Asia Pacific
- 5.4.1. Asia Pacific Menopause Market, 2018 - 2030 (USD Million)
- 5.4.2. Japan
  - 5.4.2.1. Key Country Dynamics
  - 5.4.2.2. Regulatory Framework/Scenario
  - 5.4.2.3. Competitive Scenario
  - 5.4.2.4. Japan Menopause Market, 2018 - 2030 (USD Million)
- 5.4.3. China
  - 5.4.3.1. Key Country Dynamics
  - 5.4.3.2. Regulatory Framework/Scenario
  - 5.4.3.3. Competitive Scenario
  - 5.4.3.4. China Menopause Market, 2018 - 2030 (USD Million)
- 5.4.4. India
  - 5.4.4.1. Key Country Dynamics
  - 5.4.4.2. Regulatory Framework/Scenario
  - 5.4.4.3. Competitive Scenario
  - 5.4.4.4. India Menopause Market, 2018 - 2030 (USD Million)
- 5.4.5. Australia
  - 5.4.5.1. Key Country Dynamics
  - 5.4.5.2. Regulatory Framework/Scenario
  - 5.4.5.3. Competitive Scenario
  - 5.4.5.4. Australia Menopause Market, 2018 - 2030 (USD Million)
- 5.4.6. Thailand
  - 5.4.6.1. Key Country Dynamics
  - 5.4.6.2. Regulatory Framework/Scenario
  - 5.4.6.3. Competitive Scenario
  - 5.4.6.4. Thailand Menopause Market, 2018 - 2030 (USD Million)
- 5.4.7. South Korea
  - 5.4.7.1. Key Country Dynamics
  - 5.4.7.2. Regulatory Framework/Scenario
  - 5.4.7.3. Competitive Scenario
  - 5.4.7.4. South Korea Menopause Market, 2018 - 2030 (USD Million)
5.5. Latin America
- 5.5.1. Latin America Menopause Market, 2018 - 2030 (USD Million)
- 5.5.2. Brazil
  - 5.5.2.1. Key Country Dynamics
  - 5.5.2.2. Regulatory Framework/Scenario
  - 5.5.2.3. Competitive Scenario
  - 5.5.2.4. Brazil Menopause Market, 2018 - 2030 (USD Million)
- 5.5.3. Mexico
  - 5.5.3.1. Key Country Dynamics
  - 5.5.3.2. Regulatory Framework/Scenario
  - 5.5.3.3. Competitive Scenario
  - 5.5.3.4. Mexico Menopause Market, 2018 - 2030 (USD Million)
- 5.5.4. Argentina
  - 5.5.4.1. Key Country Dynamics
  - 5.5.4.2. Regulatory Framework/Scenario
  - 5.5.4.3. Competitive Scenario
  - 5.5.4.4. Argentina Menopause Market, 2018 - 2030 (USD Million)
5.6. MEA
- 5.6.1. MEA Menopause Market, 2018 - 2030 (USD Million)
- 5.6.2. South Africa
  - 5.6.2.1. Key Country Dynamics
  - 5.6.2.2. Regulatory Framework/Scenario
  - 5.6.2.3. Competitive Scenario
  - 5.6.2.4. South Africa Menopause Market, 2018 - 2030 (USD Million)
- 5.6.3. Saudi Arabia
  - 5.6.3.1. Key Country Dynamics
  - 5.6.3.2. Regulatory Framework/Scenario
  - 5.6.3.3. Competitive Scenario
  - 5.6.3.4. Saudi Arabia Menopause Market, 2018 - 2030 (USD Million)
- 5.6.4. UAE
  - 5.6.4.1. Key Country Dynamics
  - 5.6.4.2. Regulatory Framework/Scenario
  - 5.6.4.3. Competitive Scenario
  - 5.6.4.4. UAE Menopause Market, 2018 - 2030 (USD Million)
- 5.6.5. Kuwait
  - 5.6.5.1. Key Country Dynamics
  - 5.6.5.2. Regulatory Framework/Scenario
  - 5.6.5.3. Competitive Scenario
  - 5.6.5.4. Kuwait Menopause Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

6.1. Company Categorization
6.2. Strategy Mapping
- 6.2.1. Merger& Acquisition
- 6.2.2. Collaborations
- 6.2.3. New Product Launch
6.3. Participant's overview
- 6.3.1. Bayer AG
  - 6.3.1.1. Overview
  - 6.3.1.2. Financial Performance
  - 6.3.1.3. Product Benchmarking
  - 6.3.1.4. Strategic Initiatives
- 6.3.2. Theramex
  - 6.3.2.1. Overview
  - 6.3.2.2. Financial Performance
  - 6.3.2.3. Product Benchmarking
  - 6.3.2.4. Strategic Initiatives
- 6.3.3. Abbvie Inc.
  - 6.3.3.1. Overview
  - 6.3.3.2. Financial Performance
  - 6.3.3.3. Product Benchmarking
  - 6.3.3.4. Strategic Initiatives
- 6.3.4. Abbott
  - 6.3.4.1. Overview
  - 6.3.4.2. Financial Performance
  - 6.3.4.3. Product Benchmarking
  - 6.3.4.4. Strategic Initiatives
- 6.3.5. Pure Encapsulations, LLC
  - 6.3.5.1. Overview
  - 6.3.5.2. Financial Performance
  - 6.3.5.3. Product Benchmarking
  - 6.3.5.4. Strategic Initiatives
- 6.3.6. Dr. Reddy's Laboratories Ltd.
  - 6.3.6.1. Overview
  - 6.3.6.2. Financial Performance
  - 6.3.6.3. Product Benchmarking
  - 6.3.6.4. Strategic Initiatives
- 6.3.7. Rainbow Light
  - 6.3.7.1. Overview
  - 6.3.7.2. Financial Performance
  - 6.3.7.3. Product Benchmarking
  - 6.3.7.4. Strategic Initiatives
- 6.3.8. PADAGIS LLC
  - 6.3.8.1. Overview
  - 6.3.8.2. Financial Performance
  - 6.3.8.3. Product Benchmarking
  - 6.3.8.4. Strategic Initiatives

简介目录图表

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. Global dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
Table 4. Global OTC pharma products market estimates and forecast, 2018 - 2030 (USD Million)
Table 5. North America menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 6. North America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 7. U.S. menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 8. U.S. menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 9. Canada menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 10. Canada menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 11. Europe menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 12. Europe menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 13. UK menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 14. UK menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 15. Germany menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 16. Germany menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 17. France menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 18. France menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 19. Italy menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 20. Italy menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 21. Spain menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 22. Spain menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 23. Austria menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 24. Austria menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 25. Asia Pacific menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 26. Asia Pacific menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 27. China menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 28. China menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 29. Japan menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 30. Japan menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 31. India menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 32. India menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 33. South Korea menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 34. South Korea menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 35. Latin America menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 36. Latin America menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 37. Brazil menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 38. Brazil menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 39. Mexico menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 40. Mexico menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 41. Middle East & Africa (MEA) menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 42. Middle East & Africa (MEA) menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)
Table 43. South Africa menopause market estimates and forecast, 2018 - 2030 (USD Million)
Table 44. South Africa menopause market revenue estimates and forecast by treatment, 2018 - 2030 (USD Million)